WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Monte Rosa Therapeutics earnings were -$72.7M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest GLUE earnings report on Dec 31, 2024 announced Q4 2024 earnings of $13.4M, down 156.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GLUE reported annual earnings of -$72.7M, with -46.3% growth.

GLUE earnings history

Current Revenue
$75.6M
Current Earnings
-$72.7M
Current Profit Margin
-96.1%

GLUE Return on Equity

Current Company
-36.1%
Current Industry
-2%
Current Market
34.1%
GLUE's Return on Equity (-36.1%)... subscribe to Premium to read more.
High Return on Equity Performance

GLUE undefined

Current Company
-21.3%
Current Industry
-0.4%
GLUE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when GLUE announces earnings.

GLUE undefined

Current Company
-24.89%
Current Industry
5.9%
GLUE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GLUE vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
GLUE-$62.01M-$72.70MN/A-$0.98
PHAT-$261.52M-$334.33MN/A-$5.29
AURA-$84.11M-$86.92MN/A-$1.75
PVLA-$13.12M-$17.43MN/A-$7.83
RNAC-$73.55M-$77.42MN/A-$4.48
View Top Biotech Stocks

Monte Rosa Therapeutics Earnings Reports & History FAQ

What were Monte Rosa Therapeutics's earnings last quarter?

Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q4 2024 earnings per share (EPS) of $0.23, up 140.35% year over year. Total GLUE earnings for the quarter were $13.44 million. In the same quarter last year, Monte Rosa Therapeutics's earnings per share (EPS) was -$0.57.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

Is Monte Rosa Therapeutics profitable or losing money?

As of the last Monte Rosa Therapeutics earnings report, Monte Rosa Therapeutics is currently losing money. Monte Rosa Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$72.70 million, a 46.29% decrease year over year.

What was GLUE's earnings growth in the past year?

As of Monte Rosa Therapeutics's earnings date in Q2 2025, Monte Rosa Therapeutics's earnings has grown year over year. GLUE earnings in the past year totalled -$72.70 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.